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Abstract. It is estimated that there are 4.0 million individuals chronically infected with Hepatitis C virus 
(HCV) in the US. Due to the slow progression of disease, the incidence of HCV has declined in the last 
two decades. However, it is anticipated that the number of individuals requiring treatment for liver disease 
associated with HCV will increase for years to come. Until 2011, HCV genotype 1 infections were treated 
with 48 weeks of pegylated interferon and ribavirin combination therapy; only 50% of patients had a suc-
cessful outcome. Moreover, patients often withdraw from treatment prematurely because of the high cost 
and adverse effects of therapy. All of these factors make HCV infection a serious healthcare issue. 
Recent advances in HCV management include the discovery of host genetic polymorphisms that can pre-
dict treatment outcome, as well as the availability of the first direct acting antiviral agents that promise to 
revolutionize HCV management and increase the likelihood of a favorable treatment outcome. In 2009, 
multiple independent groups performed genome-wide association studies in HCV infected individuals 
and identified several single-nucleotide polymorphisms (SNPs) near the IL28B gene that predict the likeli-
hood of both spontaneous and treatment-induced HCV clearance. This article provides an overview of the 
genome-wide association studies that uncovered the role of the IL28B genotype and reviews the clinical 
utility of IL28B genotyping.
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Hepatitis C Infection. In the United States, the 
prevalence of HCV infection has been estimated at 
over 4.0 million cases, of which 80% are suspected 
to be viremic. Because the immune system has dif-
ficulty clearing hepatitis C infection, only 15-30% 
of individuals who contract HCV clear the virus 
[1]. The remainder develop chronic hepatitis C in-
fection, which is associated with severe liver dis-
ease, including cirrhosis and hepatocellular carci-
noma. Chronic HCV infection is currently the 
primary cause for liver transplantation and also ac-
counts for approximately 10,000 deaths every year 
[1]. Acute HCV is rarely diagnosed and infected 
patients often do not have any symptoms until seri-
ous complications develop, decades post-infection. 
This underscores the importance of screening pop-
ulations that are at increased risk for HCV 
infection. 
Chronic HCV infection can be successfully treated 
and a virologic cure can be attained, reducing both 
the long-term complications and the significant 
rate of mortality and morbidity associated with 
persistent hepatitis C infection [2]. Successful treat-
ment response for HCV infection is defined as un-
detectable viremia six months after completion of 
treatment and is referred to as sustained virologic 
response (SVR).  When treated with pegylated in-
terferon and ribavirin combination therapy, pa-
tients infected with HCV genotype 1 infections 
have substantially lower rates of SVR compared to 
HCV genotypes 2 and 3, approximately 50% vs. 
80% respectively [3].  HCV genotype 1 is the most 
prevalent genotype in North America, Europe and 
Japan.   HCV genotype is the strongest pre-thera-
peutic marker for treatment-induced HCV resolu-
tion. Measuring the kinetics of viral clearance dur-
ing therapy to predict the likelihood of SVR is 
useful for all HCV genotypes.  There is a distinct 
relationship between how rapidly a patient achieves 
undetectable viremia in response to therapy and 
the likelihood of attaining SVR. A rapid viral re-
sponse (RVR), defined as a decrease in HCV viral 
load to undetectable levels at week 4 of therapy, 
strongly predicts SVR.  Although patients infected 
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with HCV genotype 1 are less likely to achieve 
RVR, its occurrence is the best predictor of SVR. 
This observation suggested the existence of host 
factors that affect the likelihood of a positive treat-
ment outcome. In addition to the limited efficacy 
of treatment, the therapy itself is difficult to toler-
ate. Individuals can experience serious side effects 
ranging from psychological depression to bone 
marrow suppression, often resulting in premature 
withdrawal from treatment [3]. Given the high cost 
of treatment, poor response rate for HCV 1, and 
severe side effects, identifying factors that predict 
response to therapy would be valuable. However, 
until the discovery of IL28B SNPs, no host genetic 
markers were available to predict likelihood of re-
sponse or drug toxicity prior to therapy. 
Genome-wide Association Studies. The human 
genome consists of approximately 3.3 billion base 
pairs and is 99.5% identical between individuals. 
This 0.5% of human genetic variation explains the 
observed differences between individuals for pre-
disposition to disease, disease course and therapy 
response. The most common form of genetic varia-
tion is sequence difference at a single nucleotide, or 
single-nucleotide polymorphism (SNP), and there 
are approximately 10-20 million such differences 
between individuals. Unraveling the genome and 
identifying the genetic variation that is responsible 
for a specific condition, such as treatment-induced 
clearance of HCV infection, is the essence of per-
sonalized medicine. 
Genome-wide association studies (GWAS) investi-
gate the genome for genetic variation or SNPs as-
sociated with a disease or condition of interest by 
utilizing high throughput technologies. If an SNP 
is overrepresented in the affected population vs. in 
the control population, then the SNP is associated 
with the condition of interest. SNPs vary in a non-
random manner within a chromosomal region and 
although SNPs may be distantly located on a chro-
mosome, they can be inherited together as a block 
or haplotype and are said to be in linkage disequi-
librium [4]. It is therefore possible for researchers to 
scan the genome with only a limited number of 
“tag” SNPs (e.g. 500,000-2,000,000) and still de-
tect polymorphisms associated with a phenotype. 
However, this strategy rarely identifies the causal 
variant associated with an observed effect. The 
causal variant SNP and the tag SNP are usually in 
varying degrees of linkage disequilibrium. The 
“tag” SNP generally marks a chromosomal region 
of interest but not a specific gene. The location and 
distribution of common SNPs and haplotypes is 
made possible by the HapMap project [5, 6]. 
Table 1. Summary of GWAS studies for HCV infection outcome.
Study              Population       HCV           SNP                   Nucleotide               Favorable 
        Genotype                Genotype
              
Ge (2009) 1671 Americans          1       rs12979860           C/T  CC
USA  Caucasian/African-
                 American/Hispanic
Suppiah (2009)  293 Europeans/          1        rs8099917  T/G  TT
Australia  Australians
Tanaka (2009)  154 Japanese          1        rs8099917  T/G  TT
Japan
Rauch (2010)   1362 Caucasians          1,2,3,4      rs8099917  T/G  TT
Switzerland
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Compared to the traditional gene candidate ap-
proach, this strategy can identify functionally im-
portant polymorphisms in genes that have an un-
expected role in disease pathogenesis. Results of 
GWAS are dependent on appropriate selection of 
control and affected populations, large sample co-
horts, and adequate statistical analysis for use with 
large data sets. In general, GWAS are successful 
when the association is strong and/or when the 
variant is relatively common, but these conditions 
are frequently not met [7, 8].  
IL28B genotype and HCV clearance. The role of 
the IL28B genotype in predicting the likelihood of 
a positive outcome response was largely discovered 
using genome-wide association studies (GWAS). 
Using various microarray technologies, several in-
dependent groups from the US, Australia, Europe, 
and Japan identified a series of SNPs associated 
with treatment outcome in populations of different 
ethnic backgrounds infected with various HCV 
genotypes (Table 1). Ge and colleagues conducted 
a genome-wide association study with US patients 
enrolled in the IDEAL trial that evaluated different 
pegylated interferon/ribavirin formulations. The 
patient cohort consisted of over 1,600 patients of 
different ethnic backgrounds, including 
Caucasians, African-Americans, and Hispanics [9]. 
Data demonstrated that patients with the 
rs12979860 CC genotype were twice as likely to 
achieve SVR than were CT-heterozygous or TT-
homozygous individuals. This effect was observed 
regardless of ethnic background. Even African-
Americans carrying the CC genotype were likely to 
achieve SVR, an exciting finding as it is well known 
that African-Americans are less likely to be cured 
by treatment than are Caucasians.  The IL28B gen-
otype only partially explains the differential thera-
py response rates between African-Americans and 
Caucasians [9, 10].
Tanaka’s group used the Affymetrix genotyping 
platform to test the non-responder phenotype in a 
Japanese cohort and identified the rs8099917 SNP 
as the strongest predictor of non-response, inde-
pendent of other clinical variables [11]. For the 
rs8099917 T/G SNP, T is the favorable and G the 
risk allele. The Affymetrix microarray did not in-
clude the rs12979860 tag SNP discovered by Ge. 
Suppiah assessed an Australian patient cohort and 
regression analysis further confirmed the IL28B 
genotype as an independent predictor of significant 
SVR rates [12].  
The IL28B genotype has also been implicated in 
spontaneous HCV clearance. Ge first reported that 
the CC favorable genotype was present at a reduced 
frequency in the control population compared to 
the HCV infected cohort, suggesting that the 
IL28B genotype also played a critical role in spon-
taneous clearance. Thomas specifically addressed 
the association of the IL28B with spontaneous 
clearance using an ethnically diverse population 
composed of six clinical trial cohorts and found 
that the CC genotype for rs12979860 was present 
2.5 times more frequently in patients that resolved 
HCV infection in the absence of treatment [10]. To 
gain insight into the variable HCV resolution rates 
observed across different ethnic groups, the investi-
gators genotyped 2,371 persons from 51 popula-
tions worldwide and determined the global distri-
bution of the rs12979860 alleles. The protective C 
allele dominated in Asia, was of intermediate fre-
quency in Europe, and was rare in Africa. The data 
were consistent with the differential rates of HCV 
clearance noted globally. The Rauch group assessed 
347 patients who spontaneously cleared HCV, 
1062 patients with persistent HCV infection (HCV 
genotypes 1-4), and 448 HIV/HCV coinfected 
persons. Both chronic hepatitis C infection and 
treatment failure were associated with the risk allele 
for rs8099917. The IL28B genotype effect was 
strongest in individuals infected with HCV geno-
types 1 and 4. The IL28B genotype predicted spon-
taneous clearance, but HIV coinfection did not 
modulate the effects of the IL28B genotype [13]. 
Initial GWAS identified SNPs associated with 
HCV clearance. Subsequent studies addressed the 
significance and predictive power of the SNPs. 
McCarthy and colleagues conducted a candidate 
gene approach and determined that the rs12979860 
CC genotype predicted SVR in Caucasians inde-
pendently of other covariates, including HCV gen-
otype [14]. Studies by Thompson and colleagues 
further investigated the clinical utility of the IL28B 
genotype in patients infected with HCV genotype 
1 and concluded that the IL28B genotype is the 
strongest pre-treatment predictor compared 
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to previously described host markers including 
gender, age, steatosis, insulin resistance, and base-
line viral load. However, rapid viral response (RVR) 
remains the strongest predictor of SVR, irrespec-
tive of IL28B genotype. In the group that did not 
achieve RVR, patients with the favorable 
rs12979860 CC genotype were twice as likely to 
attain SVR compared to non-CC genotypes [15]. 
In Caucasians infected with HCV genotype 1 and 
treated with standard of care therapy (pegylated in-
terferon and ribavirin therapy), SVR rates were 
69%, 33%, and 27% for CC, CT, and TT geno-
types, respectively. For African-Americans, SVR 
rates were 48%, 15% and 13% , for CC, CT and 
TT genotypes, respectively [15]. Altogether, nu-
merous studies have provided indisputable support 
for the role of the IL28B genotype as a predictor of 
both spontaneous and treatment-induced HCV 
clearance.
IL28B and HIV/HCV coinfections. 
Approximately one-third of HIV-positive individu-
als are coinfected with HCV. Many studies have 
confirmed that the IL28B genotype is a significant 
and independent predictor of SVR and spontane-
ous clearance in this population as well [10, 13, 16-
18]. As is the case with HCV mono-infected popu-
lations the strongest effect is with HCV genotypes 
1 and 4 [10, 13]. Although favorable IL28B geno-
type is associated with a positive HCV treatment 
outcome, one group recently reported that the 
IL28B genotype is associated with increased mor-
tality in coinfected populations [19].  More data are 
needed before specific recommendations can be 
made for the treatment of HIV/HCV coinfected 
individuals. 
IL28B and transplantation. Not only is HCV in-
fection the leading cause of liver transplants, HCV 
recurrence is also almost guaranteed in patients 
who are viremic at the time of transplantation. 
Treatment in the post-transplant setting is compli-
cated by drug-drug interactions, risk of toxicity, 
and transplant rejection. In general, achieving SVR 
is a challenge. Therefore, numerous researchers 
have recently investigated the role of the IL28 gen-
otype in predicting liver transplant success. 
Published reports suggest that: 1) the favorable 
IL28B genotype is less frequent in HCV patients 
who have severe liver disease and need a transplant; 
2) both donor and recipient IL28B genotype have 
an effect on the likelihood of achieving SVR in a 
post-transplant setting;  3) the association between 
the IL28B genotype and other liver transplant out-
comes is not as clear [20-25]. More definitive stud-
ies are necessary before IL28 genotype information 
in the setting of post-liver transplant can be inte-
grated into clinical practice.
IL28B and direct-acting antiviral agents. The 
discovery that host genetic variation is associated 
with significant SVR rates is only one of the impor-
tant developments in HCV management that have 
occurred in the last two years. The other major ad-
vance is the introduction of the first class of drugs 
that specifically target HCV, are referred to as di-
rect-acting antiviral agents (DAAs). The first DAAs 
to be cleared by the FDA for use in the US, 
Telaprevir and Boceprevir, are both NS3/4A serine 
protease inhibitors. The significance of the IL28B 
genotype was originally discovered in patients in-
fected with HCV who were undergoing standard 
of care treatment (pegylated interferon and ribava-
rin).  The addition of a protease inhibitor to SOC, 
referred to as triple therapy, has been shown to sig-
nificantly increase SVR rates to 80% in HCV gen-
otype 1 infected patients, but has called into ques-
tion the relevance of IL28B polymorphisms [26, 
27]. Triple therapy is now the optimal treatment 
regimen for HCV genotype 1 patients [28]. The 
IL28B genotype remains predictive of SVR in per-
sons being treated with triple therapy [29, 30]. 
Because higher SVR rates are observed in HCV 
genotype 1 patients on triple therapy compared to 
those on SOC,  guidelines do not recommend one 
therapy over another based on IL28 genotype [28]. 
However, patients with a favorable IL28B genotype 
are more likely to have abbreviated therapy under 
triple therapy regimens [29-31]. 
IL28B mechanism. The mechanism by which the 
IL28B genotype exerts its effects is the target of in-
tense investigation. All SNPs that had a strong as-
sociation with HCV clearance mapped to the re-
gion of IL28A, IL28B, and IL29 interleukin genes 
on chromosome 19q13. These genes encode a 
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recently discovered family of interferons known as 
type III or lambda interferons. Lambda interferons 
have been shown to inhibit HCV in vitro and are 
believed to trigger an anti-viral cascade through 
the JAK-STAT pathway [32, 33]. The two SNPs 
with the strongest association for treatment re-
sponse, rs12979860 and rs8099917, are in linkage 
disequilibrium, approximately 4 kb apart, and are 
both located upstream of IL28B. The upstream lo-
cation of IL28B prompted investigators to postu-
late that the causal variant affects gene transcrip-
tion. Expression studies, however, have yielded 
mixed results. While the biological mechanism 
behind the IL28B genotype remains to be deter-
mined, the overwhelming evidence indicates that it 
is a critical and independent factor in HCV 
clearance.
IL28B genotype in clinical practice. Today, 
commonly utilized genotyping technologies such 
as TaqMan allelic discrimination and dual-color 
fluorescence resonance energy (FRET) are com-
mercially available for IL28B genotyping [34]. 
Ultimately, two SNPs (rs12979860 and rs8099917) 
were shown to have the strongest association with 
both spontaneous and treatment-induced HCV 
clearance and became candidates for IL28B geno-
type assays. While these two SNPs are in linkage 
disequilibrium, the degree of linkage disequilibri-
um varies with ethnic background [9, 13, 34, 35]. 
These data indicate that the two SNPs provide in-
terchangeable information in Caucasians, for ex-
ample, but not in populations with weak linkage, 
such as African-Americans. In multiple studies, the 
rs12979860 CC favorable genotype was clearly as-
sociated with a significant rate of SVR in African-
Americans [9, 10]. Few studies have genotyped for 
both SNPs and evaluated HCV clearance. 
Although there are limited data that suggest the 
rs12979860 may be the more relevant SNP, in pa-
tients who are discordant for these two SNPs it is 
not well established which of the two SNPs is more 
reflective of observed response. 
In summary, IL28B genotyping is a strong pre-
treatment predictor of SVR in patients with HCV 
genotype 1 infections irrespective of treatment 
regimen (SOC or triple therapy).  Predictive value 
is lower in patients infected with HCV genotypes 2 
and 3 [13, 28, 36]. Therapy (SOC or triple therapy) 
selection and duration for HCV genotype 1 infec-
tions should not be based on  IL28 status. According 
to current guidelines, the IL28B genotype should 
be considered if information regarding the likeli-
hood of a positive response and probable duration 
of response is useful for the clinician and patient 
[28]. Most importantly, not all patients with a fa-
vorable IL28B genotype are guaranteed to have a 
successful therapy outcome and conversely, not all 
patients with a risk genotype are destined to fail 
therapy.
Conclusion
It had long been suspected that host genetics con-
tributed to an individual’s ability to clear HCV in-
fection, but it was gene-wide association studies 
which first identified the IL28B genotype as a pow-
erful predictor for both spontaneous and treat-
ment-induced clearance. Currently, the IL28B 
genotype has limited clinical use and serves pri-
marily as a strong pre-treatment predictor, most 
useful for HCV genotype 1 infected patients un-
dergoing either standard of care or triple therapy 
treatment regimens. The IL28B genotype may play 
a more active role in patient management in the 
future, with the integration of other therapeutic 
agents that target a myriad of processes in the viral 
lifecycle; these pharmaceuticals are in various stag-
es of clinical trials. Cost-benefit analysis based on 
successful response to a growing number of thera-
peutic options and IL28B genotype may also alter 
future recommendations for the clinical use of the 
IL28B genotype.
References
1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, 
Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus 
infection in the United States, 1999 through 2002. Ann Intern 
Med 2006; 144: 705-714.
2. Morgan T, Ghany M, Kim H, Snow K, Shiffman ML, De 
Santo J, Lee W, Di Bisceglie A, Bonkovsky H, Dienstag J, 
Morishima C, Lindsay K, Lok AS. Outcome of sustained viro-
logical responders with histologically  advanced chronic hepa-
titis C.  Hepatology 2010; 52: 833-844.
3. Fried M, Shiftman M, Reddy K, Smith C, Marinos G, 
Gonzales FLJ, et.al. Peginterferon alfa-2-a plus riboflavin for 
chronic hepatitis C virus infections. N Engl J Med 2002; 347: 
975-982.
Host Genomics and HCV Personalized Medicine 367
4. Goldstein DB, Weale ME. Population genomics: linkage dis-
equilibrium holds the key. Curr Biol 2001; 11: R576-579.
5. International HapMap C. A haplotype map of the human ge-
nome. Nature 2005; 437: 1299-1320.
6. International HapMap C, Frazer KA, Ballinger DG, Cox DR, 
Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, 
Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, 
Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu 
S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, 
Zhao H, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, 
Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, 
Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, 
Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang 
W, Chu X, He Y, Jin L, Liu Y, Shen Y, Sun W, Wang H, Wang 
Y, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong 
JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant 
AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf 
M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, 
Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, 
Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, 
Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, 
Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, 
Tsunoda T, Deloukas P, Bird CP, Delgado M, Dermitzakis ET, 
Gwilliam R, Hunt S, Morrison J, Powell D, Stranger BE, 
Whittaker P, Bentley DR, Daly MJ, de Bakker PI, Barrett J, 
Chretien YR, Maller J, McCarroll S, Patterson N, Pe’er I, Price 
A, Purcell S, Richter DJ, Sabeti P, Saxena R, Schaffner SF, 
Sham PC, Varilly P, Altshuler D, Stein LD, Krishnan L, Smith 
AV, Tello-Ruiz MK, Thorisson GA, Chakravarti A, Chen PE, 
Cutler DJ, Kashuk CS, Lin S, Abecasis GR, Guan W, Li Y, 
Munro HM, Qin ZS, Thomas DJ, McVean G, Auton A, 
Bottolo L, Cardin N, Eyheramendy S, Freeman C, Marchini J, 
Myers S, Spencer C, Stephens M, Donnelly P, Cardon LR, 
Clarke G, Evans DM, Morris AP, Weir BS, Tsunoda T, 
Mullikin JC, Sherry ST, Feolo M, Skol A, Zhang H, Zeng C, 
Zhao H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi 
CN, Adebamowo CA, Ajayi I, Aniagwu T, Marshall PA, 
Nkwodimmah C, Royal CD, Leppert MF, Dixon M, Peiffer A, 
Qiu R, Kent A, Kato K, Niikawa N, Adewole IF, Knoppers 
BM, Foster MW, Clayton EW, Watkin J, Gibbs RA, Belmont 
JW, Muzny D, Nazareth L, Sodergren E, Weinstock GM, 
Wheeler DA, Yakub I, Gabriel SB, Onofrio RC, Richter DJ, 
Ziaugra L, Birren BW, Daly MJ, Altshuler D, Wilson RK, 
Fulton LL, Rogers J, Burton J, Carter NP, Clee CM, Griffiths 
M, Jones MC, McLay K, Plumb RW, Ross MT, Sims SK, 
Willey DL, Chen Z, Han H, Kang L, Godbout M, Wallenburg 
JC, L’Archeveque P, Bellemare G, Saeki K, Wang H, An D, Fu 
H, Li Q, Wang Z, Wang R, Holden AL, Brooks LD, McEwen 
JE, Guyer MS, Wang VO, Peterson JL, Shi M, Spiegel J, Sung 
LM, Zacharia LF, Collins FS, Kennedy K, Jamieson R, Stewart 
J. A second generation human haplotype map of over 3.1 mil-
lion SNPs. Nature 2007; 449: 851-861.
7. Pe’er I, de Bakker PI, Maller J, Yelensky R, Altshuler D, Daly 
MJ. Evaluating and improving power in whole-genome associ-
ation studies using fixed marker sets. Nat Genet 2006; 38: 
663-667.
8. Goldstein DB. Common genetic variation and human traits. N 
Engl J Med 2009; 360: 1696-1698.
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban 
TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, 
McHutchison JG, Goldstein DB. Genetic variation in IL28B 
predicts hepatitis C treatment-induced viral clearance. Nature 
2009; 461: 399-401.
10. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, 
Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk 
GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, 
McHutchison JG, Goldstein DB, Carrington M. Genetic vari-
ation in IL28B and spontaneous clearance of hepatitis C virus. 
Nature 2009; 461: 798-801.
11. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, 
Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito 
Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, 
Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura 
M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga 
K, Mizokami M. Genome-wide association of IL28B with re-
sponse to pegylated interferon-alpha and ribavirin therapy for 
chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
12. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, 
Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, 
Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, 
Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated 
with response to chronic hepatitis C interferon-alpha and riba-
virin therapy. Nat Genet 2009; 41: 1100-1104.
13. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller 
T, Bochud M, Battegay M, Bernasconi E, Borovicka J, 
Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, 
Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt 
B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, 
Telenti A, Bochud PY, Swiss Hepatitis CCS, Swiss HIVCS. 
Genetic variation in IL28B is associated with chronic hepatitis 
C and treatment failure: a genome-wide association study. 
Gastroenterology 2010; 138: 1338-1345, 1345 e1331-1337.
14. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, 
Patel K, Tillmann HL, Muir AJ, McHutchison JG. Replicated 
association between an IL28B gene variant and a sustained re-
sponse to pegylated interferon and ribavirin. Gastroenterology 
2010; 138: 2307-2314.
15. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna 
KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad 
F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, 
Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, 
Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel 
K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass 
CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-
28B polymorphism improves viral kinetics and is the strongest 
pretreatment predictor of sustained virologic response in geno-
type 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129 
e118.
16. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, 
Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison 
J, Soriano V. Association of a single nucleotide polymorphism 
near the interleukin-28B gene with response to hepatitis C 
therapy in HIV/hepatitis C virus-coinfected patients. AIDS 
2010; 24: F23-29.
17. Labarga P, Barreiro P, Mira JA, Vispo E, Rallon N, Neukam K, 
Camacho A, Caruz A, Rodriguez-Novoa S, Pinilla J, Rivero A, 
Benito JM, Pineda JA, Soriano V. Impact of IL28B polymor-
phisms on response to peginterferon and ribavirin in HIV-
hepatitis C virus-coinfected patients with prior nonresponse or 
relapse. AIDS 2011; 25: 1131-1133.
18. Aparicio E, Parera M, Franco S, Perez-Alvarez N, Tural C, 
Clotet B, Martinez MA. IL28B SNP rs8099917 is strongly as-
sociated with pegylated interferon-alpha and ribavirin therapy 
treatment failure in HCV/HIV-1 coinfected patients. PLoS 
ONE 2010; 5: e13771.
19. Clausen LN, Astvad K, Ladelund S, Larsen MV, Schonning K, 
Benfield T. Hepatitis C viral load, genotype 3 and interleukin-
28B CC genotype predict mortality in HIV and hepatitis 
C-coinfected individuals. AIDS 2012; 26: 1509-1516.
20. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt 
KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-
Vorackova F, Charlton MR. The Course of Posttransplant 
Annals of Clinical & Laboratory Science, vol. 42, no. 4, 2012368
Hepatitis C Infection: Comparative Impact of Donor and 
Recipient Source of the Favorable IL28B Genotype and Other 
Variables. Transplantation 2012; 94: 197-203.
21. Cisneros E, Banos I, Citores MJ, Duca A, Salas C, Noblejas A, 
Canizares M, Millan I, Cuervas-Mons V, Vilches C. Increased 
Risk of Severe Hepatitis C Virus Recurrence After Liver 
Transplantation in Patients With a T Allele of IL28B 
rs12979860. Transplantation 2012.
22. Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram 
R, Neuhaus P, Neumann U, Seehofer D. Role of IL28B poly-
morphism in the development of hepatitis C virus-induced he-
patocellular carcinoma, graft fibrosis, and posttransplant anti-
viral therapy. Transplantation 2012; 93: 644-649.
23. Lange CM, Moradpour D, Doehring A, Lehr HA, Mullhaupt 
B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, 
Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, 
Lotsch J, Zeuzem S, Hofmann WP. Impact of donor and re-
cipient IL28B rs12979860 genotypes on hepatitis C virus liver 
graft reinfection. J Hepatol 2011; 55: 322-327.
24. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, 
Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. 
Interleukin-28B polymorphisms are associated with histologi-
cal recurrence and treatment response following liver trans-
plantation in patients with hepatitis C virus infection. 
Hepatology 2011; 53: 317-324.
25. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya 
A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, 
Maehara Y. Variants in IL28B in liver recipients and donors 
correlate with response to peg-interferon and ribavirin therapy 
for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-
1585, 1585 e1571-1573.
26. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, 
Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, 
Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, 
Bronowicki JP. Boceprevir for untreated chronic HCV geno-
type 1 infection. N Engl J Med 2011; 364: 1195-1206.
27. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, 
Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, Team 
PS. Telaprevir with peginterferon and ribavirin for chronic 
HCV genotype 1 infection. N Engl J Med 2009; 360: 
1827-1838.
28. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB.. 
An update on treatment of genotype 1 chronic hepatitis C virus 
infection: 2011 practice guideline by the American Association 
for the Study of Liver Diseases. Hepatology 2011; 54: 
1433-1444.
29. Poordad F, Bronowicki JP, Gordon S, Zeuzem S, Jacobson IM, 
Sulkowski M.IL28B polymorphism predicts virological re-
sponse in patients with chronic hepatitis C genotype 1 treated 
with boceprevir (BOC) combination therapy. J Hepatol 2011; 
54 S6.
30. Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AT, 
Adda N. Telaprevir substantially improves SVR rates across all 
IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54: 
S1369.
31. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, 
Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, 
Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada 
H. Amino acid substitution in hepatitis C virus core region and 
genetic variation near the interleukin 28B gene predict viral 
response to telaprevir with peginterferon and ribavirin. 
Hepatology 2010; 52: 421-429.
32. Thio CL, Thomas DL. Interleukin-28b: a key piece of the hepa-
titis C virus recovery puzzle. Gastroenterology 2010; 138: 
1240-1243.
33. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits 
hepatitis B and C virus replication. J Virol 2005; 79: 
3851-3854.
34. Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley 
LM, Slev PR. Simultaneous genotyping of rs12979860 and 
rs8099917 variants near the IL28B locus associated with HCV 
clearance and treatment response. J Mol Diagn 2011; 13: 
446-451.
35. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami 
M. lambda-Interferons and the single nucleotide polymor-
phisms: A milestone to tailor-made therapy for chronic hepati-
tis C. Hepatol Res 2010; 40: 449-460.
36. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann 
HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, 
Carretta V, Minerva N, Goldstein DB, McHutchison JG. An 
IL28B polymorphism determines treatment response of hepati-
tis C virus genotype 2 or 3 patients who do not achieve a rapid 
virologic response. Gastroenterology 2010; 139: 821-827, 827 
e821.
Host Genomics and HCV Personalized Medicine 369
